GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akouos Inc (NAS:AKUS) » Definitions » EV-to-EBITDA

Akouos (Akouos) EV-to-EBITDA : -4.01 (As of May. 05, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Akouos EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Akouos's enterprise value is $357.06 Mil. Akouos's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 was $-89.13 Mil. Therefore, Akouos's EV-to-EBITDA for today is -4.01.

The historical rank and industry rank for Akouos's EV-to-EBITDA or its related term are showing as below:

AKUS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -99769.57   Med: 0   Max: 1956196.21
Current: -4.01

During the past 4 years, the highest EV-to-EBITDA of Akouos was 1956196.21. The lowest was -99769.57. And the median was 0.00.

AKUS's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.55 vs AKUS: -4.01

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-05), Akouos's stock price is $13.29. Akouos's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $-2.620. Therefore, Akouos's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Akouos EV-to-EBITDA Historical Data

The historical data trend for Akouos's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akouos EV-to-EBITDA Chart

Akouos Annual Data
Trend Dec18 Dec19 Dec20 Dec21
EV-to-EBITDA
- - -8.29 -1.08

Akouos Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.52 -1.08 0.17 -0.14 -1.30

Competitive Comparison of Akouos's EV-to-EBITDA

For the Biotechnology subindustry, Akouos's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akouos's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akouos's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Akouos's EV-to-EBITDA falls into.



Akouos EV-to-EBITDA Calculation

Akouos's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=357.056/-89.125
=-4.01

Akouos's current Enterprise Value is $357.06 Mil.
Akouos's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-89.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akouos  (NAS:AKUS) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Akouos's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=13.29/-2.620
=At Loss

Akouos's share price for today is $13.29.
Akouos's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.620.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Akouos EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Akouos's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Akouos (Akouos) Business Description

Traded in Other Exchanges
N/A
Address
645 Summer Street, Suite 200, Boston, MA, USA, 02210
Akouos Inc is a genetic medicine company focused on developing gene therapies that restore, improve, and preserve hearing. The company is involved in developing potential genetic medicines for a variety of inner ear disorders.
Executives
Kearny Acquisition Corp 10 percent owner LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Lilly Eli & Co 10 percent owner LILLY CORPORATE CENTER, DROP CODE 1094, INDIANAPOLIS IN 46285
Jennifer Anne Wellman officer: Chief Operating Officer C/O AKOUOS, INC., 645 SUMMER STREET, SUITE 200, BOSTON MA 02210
Sachiyo Minegishi officer: Chief Financial Officer C/O AKOUOS, INC., 645 SUMMER STREET, SUITE 200, BOSTON MA 02210
5am Ventures V, L.p. 10 percent owner 2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Kush Parmar director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Maha Katabi 10 percent owner SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Sofinnova Venture Partners X, L.p. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Pivotal Bioventure Partners Fund I G.p., L.p. 10 percent owner 501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
New Enterprise Associates 16, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Heather Preston director, 10 percent owner C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, FORT WORTH TX 76102

Akouos (Akouos) Headlines

From GuruFocus

SHAREHOLDER ALERT: Weiss Law Investigates Akouos, Inc.

By PRNewswire PRNewswire 10-21-2022

Akouos to Present at Bank of America 2022 Healthcare Conference

By GuruFocusNews GuruFocusNews 05-04-2022